Navigation Links
Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Date:11/12/2009

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. This conference is well attended and will include several hundred institutional investors with more than one hundred healthcare management teams presenting.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... Feb. 5 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: PSX; Nasdaq: ... Shareholders on the afternoon of Wednesday 6th February. ... following morning to,review the quarter and answer investor ... (Sydney), on Thursday 7th February,(Wednesday 6thFebruary, at 4.30pm ...
... Blue Cross and Blue Shield of,Texas (BCBSTX) is ... integrated medical-dental program. The program is unique in ... dental data to,create a customized plan aimed to ... specifically help users optimize their overall health by,making ...
... STEWARTVILLE, Minn., Feb. 4 Rochester Medical,Corporation (Nasdaq: ... ending December 31, 2007., The Company reported sales ... the first quarter of last year. It also reported,net ... to a net income,of $31,467,000 or $2.59 per diluted ...
Cached Biology Technology:Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 2Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 4Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 5Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 6Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 7
(Date:4/23/2014)... study to date of the family of bacteria ... vaccine strategies and reveals surprising findings about the ... alter public health strategies to control this respiratory ... , Genomic analysis of 343 strains of the ... world collected over the last 100 years illustrates ...
(Date:4/23/2014)... 2014 A biomedical engineer at the University of ... to make blood transfusions safer. His work is supported ... of Health (NIH). , Blood transfusions save millions ... medicine,s absolute necessities. Without them, for instance, routine surgeries ... perfect, however. There,s strong evidence that transfusions of red ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... Major League Baseball pitchers indicates that the height of the ... may lead to potential injuries because of stress on the ... by William Raasch, M.D., associate professor of orthopaedic surgery at ... the head team physician for the Milwaukee Brewers. Major League ...
... a way that had never been observed in any ... Biology, a Cell Press publication. The discoverywhich marks the ... perceive circular polarized light may lend mantis shrimp a ... a new dimension of vision, said Justin Marshall of ...
... Purdue University researchers have identified several soybean varieties that ... Indiana and are resistant to root-knot nematodes, a plant-destroying ... of the state. The researchers verified that resistance ... well the plant will fight off another nematode species, ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3Soybean varieties viable in southern Indiana, resistant to root-knot nematode 2Soybean varieties viable in southern Indiana, resistant to root-knot nematode 3
Transfection Buffer A & B Set 5 ml each...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
... 209/ pSer 211 ] affinity isolated antibody ... phosphate buffered saline (without Mg 2+ and ... BSA (IgG and protease free) and 0.05% sodium ... region of mouse Hck that contains tyrosine 207 ...
Biology Products: